IPP Bureau
Bavarian Nordic seeks EMA nod for Mpox vaccine in children aged 2–11
By IPP Bureau - March 31, 2026
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
Agilent bags FDA nod for key cancer diagnostic
By IPP Bureau - March 31, 2026
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
GSK seeks European nod for promising Hepatitis B therapy
By IPP Bureau - March 31, 2026
ENHERTU approved in China as first HER2-targeted ADC for early breast cancer
By IPP Bureau - March 31, 2026
The decision is based on the phase 3 DESTINY-Breast11 trial
Roche launches groundbreaking multiplex test to boost blood safety
By IPP Bureau - March 31, 2026
The new assay consolidates screening for four major viral threats into a single workflow
Teva hits major biosimilar milestones with FDA nod and regulatory filings
By IPP Bureau - March 31, 2026
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
Allergan Aesthetics showcases breakthroughs at AAD 2026
By IPP Bureau - March 31, 2026
Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments
Bristol Myers Squibb’s Camzyos shows breakthrough results in adolescents with obstructive hypertrophic cardiomyopathy
By IPP Bureau - March 31, 2026
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
Lupin receives FDA’s tentative approval for Sugammadex injection
By IPP Bureau - March 31, 2026
Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery
Corona Remedies acquires antiseptic brand Wokadine from Dr Reddy’s to enter Iodine market
By IPP Bureau - March 31, 2026
This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
HRV Pharma and Shodhana Laboratories forge CDMO Alliance
By IPP Bureau - March 31, 2026
The partnership has already launched with five active development programs, with both organizations jointly managing regulatory strategy and documentation under a structured, milestone-gated framework
Apollo Hospitals expands air ambulance services offerings
By IPP Bureau - March 31, 2026
Over the past few months, Apollo Hospitals has entered into MoUs with multiple national and international air ambulance service providers
Granules Life Sciences receives VAI Classification for Shamirpet facility
By IPP Bureau - March 31, 2026
The inspection is now closed, and no regulatory action has been recommended
Novo Nordisk India sets patient-centred price of Rs. 202/day for starting dose of Ozempic and Wegovy
By IPP Bureau - March 31, 2026
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
